



Niclas Adler
Executive Chairman
NGT-Partners

Niclas Adler obtained his MBA at the Stockholm School of Economics in 1994, where in 1999 he also obtained his PhD in Business Administration with the thesis, entitled "Managing complex product development: Three approaches."

Adler started his academic career both at Stockholm School of Economics and the Chalmers University of Technology in 1994, where he was Associate Professor and Director of FENIX until 2005. In cooperation with the Stockholm School of Economics in 1996 he co-founded its Center for Management Innovations, and was Program Director and Fellow until 2005. In 1998 he also co-founded the Stockholm School of Entrepreneurship, and was its Executive Director for two years.

From 2007 to 2011 he was Professor of Jönköping International Business School, as well as its CEO and its Dean. In 2011 he was appointed Babson Global Professor of Entrepreneurship Practice at Babson College in the United States. In 2012 he is appointed professor at and president of the IPMI International business school, professor and president for Indonesia International Institute for Life-sciences, i3L and back in Sweden Adjunct Professor of Entrepreneurship at the Royal College of Music in Stockholm.

Adler co-founded 21 technology and innovation-based companies, including Immune Therapy Holdings, TLA Targeted Immuno Therapies, Immuno Diagnostics, Immune System Regulation in Stockholm, True Point in Boston, E-Cognition in Singapore, Kinglory Technologies and Accelerated Innovation Group in Hong Kong. Adler is chairman and board members in several technology and innovation based companies including Chairman for NASDAQ listed Karolinska Development and he is presently the Chairman for NGT Partners that manages VC and PE funds dedicated to life-science companies and technologies.

